Sort   by:  
 Page size 
UnknownTafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.
Not available
S-EPMC10797539 | biostudies-literature
UnknownIdentifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
Not available
S-EPMC10514205 | biostudies-literature
UnknownOutcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.
Not available
S-EPMC12626236 | biostudies-literature
UnknownCOVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Not available
S-EPMC8313815 | biostudies-literature
UnknownAssociation of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancer.
Not available
S-EPMC7483417 | biostudies-literature
UnknownOutcomes of COVID-19 in patients with CLL: a multicenter international experience.
Not available
S-EPMC7472711 | biostudies-literature
UnknownOvarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Not available
S-EPMC7735771 | biostudies-literature
UnknownRisks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Not available
S-EPMC10170303 | biostudies-literature
UnknownPREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.
Not available
S-EPMC10182045 | biostudies-literature
UnknownCharacterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Not available
S-EPMC7333177 | biostudies-literature
Sort   by:  
 Page size